- Report
- October 2024
- 70 Pages
Asia Pacific
From €844EUR$950USD£728GBP
- Report
- October 2024
- 70 Pages
Europe
From €844EUR$950USD£728GBP
- Report
- October 2024
- 70 Pages
China
From €844EUR$950USD£728GBP
- Report
- October 2024
- 70 Pages
France
From €844EUR$950USD£728GBP
- Report
- October 2024
- 70 Pages
Germany
From €844EUR$950USD£728GBP
- Report
- October 2024
- 70 Pages
India
From €844EUR$950USD£728GBP
- Report
- October 2024
- 70 Pages
Japan
From €844EUR$950USD£728GBP
- Report
- October 2024
- 70 Pages
United Kingdom
From €844EUR$950USD£728GBP
- Report
- October 2024
- 70 Pages
United States
From €844EUR$950USD£728GBP
- Report
- December 2023
- 132 Pages
Global
From €844EUR$950USD£728GBP
- Report
- January 2025
- 132 Pages
Global
From €844EUR$950USD£728GBP
- Book
- April 2022
- 288 Pages
- Book
- December 2011
- 368 Pages
- Book
- February 2024
North America

Asthma is a chronic respiratory condition that affects the airways of the lungs. It is characterized by inflammation, narrowing of the airways, and increased mucus production, which can lead to difficulty breathing, wheezing, and coughing. Asthma is one of the most common chronic diseases in the world, and is a major cause of morbidity and mortality.
The asthma market within the context of pulmonary medicine is a rapidly growing sector, with a wide range of products and services available to treat and manage the condition. These include inhalers, nebulizers, and other devices to deliver medication, as well as monitoring and diagnostic tools. In addition, there are a variety of medications available to treat asthma, including corticosteroids, bronchodilators, and leukotriene modifiers.
Some of the major companies in the asthma market include GlaxoSmithKline, Merck, Novartis, Boehringer Ingelheim, and AstraZeneca. Show Less Read more